{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:28:21Z","timestamp":1776270501625,"version":"3.50.1"},"reference-count":118,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of this review was to analyze the discontinuation rates during long\u2010term treatment with second\u2010generation antipsychotic long\u2010acting injection (SGA\u2010LAI) in adults with either schizophrenia spectrum or bipolar disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search (PubMed, Scopus, and the Cochrane Library) of studies published in English (1 January 2001\u201312 October 2018) identified 1214 abstracts, which were analyzed independently by the author and two colleagues. Studies were retrieved and reviewed if they reported primary data on the discontinuation rate before the study end during treatment lasting \u226536 weeks. Data were extracted from 51 articles meeting the inclusion criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all head\u2010to\u2010head comparisons, and studies on patients with schizophrenia spectrum or bipolar disorders, the discontinuation rate before the study end in patients treated with SGA\u2010LAI was, at best, similar to that recorded in patients treated with first\u2010generation antipsychotics in either oral or LAI formulations or with oral SGA. In particular, in most of the SGA\u2010LAI long\u2010term studies, the rate of premature dropout was higher than 50%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Reviewed data suggest that SGA\u2010LAI show no clear superiority over less expensive drugs (including first\u2010generation antipsychotic LAI and oral antipsychotic formulations) in reducing the risk of premature antipsychotic discontinuation. Thus, alternative strategies should be considered to improve medication persistence and lower discontinuation rates in patients with severe psychiatric disorders. Planning tailored, individualized, and integrated approaches (including frequent clinical evaluations, and behavioral or other flexible techniques adaptable to different settings and patients) may be an effective intervention for improving patient adherence in long\u2010term pharmacological treatment regimens.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pcn.12824","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T07:24:54Z","timestamp":1548660294000},"page":"216-230","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Discontinuation rates during long\u2010term, second\u2010generation antipsychotic long\u2010acting injection treatment: A systematic review"],"prefix":"10.1111","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8303-725X","authenticated-orcid":false,"given":"Salvatore","family":"Gentile","sequence":"first","affiliation":[{"name":"Department of Mental Health ASL Salerno\u2013Italy  Salerno Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"MurrayCJ LopezAD World Health Organization World Bank and Harvard School of Public Health.The global burden of disease: A comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020(Vol. 1). World Health Organization Geneva 1996."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.10.1447"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000293161"},{"key":"e_1_2_7_5_1","first-page":"357","article-title":"Global economic burden of schizophrenia: A systematic review","volume":"12","author":"Chong HY","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"e_1_2_7_6_1","first-page":"S85","article-title":"Bipolar disorder. Costs and comorbidity","volume":"11","author":"Hirschfeld RMA","year":"2005","journal-title":"Am. J. Manag. Care"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.09.011"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v6.i4.399"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.8.886"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2009.05.004"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0715"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2009.00589.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300001"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.195.52.s37"},{"key":"e_1_2_7_16_1","first-page":"113","article-title":"Formulation optimization of long\u2010acting depot injection of aripiprazole by using D\u2010optimal mixture design","volume":"63","author":"Nahata T","year":"2009","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"e_1_2_7_17_1","unstructured":"Johnson & Johnson. Janssen submits new drug application to U.S. FDA for three\u2010month paliperidone palmitate first long\u2010acting treatment to be used four times a year for schizophrenia in adults. 19 November 2014. [Cited 22 February 2017.] Available from URL:http:\/\/www.investor.jnj.com\/releasedetail.cfm?releaseid=883843"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1191945"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0241"},{"key":"e_1_2_7_20_1","unstructured":"Johnson & Johnson. European Commission Approves TREVICTA\u00ae (paliperidone palmitate a 3\u2010monthly injection) for Maintenance Treatment of Schizophrenia. [Cited 8 February 2017.] Available from URL:http:\/\/www.investor.jnj.com\/releasedetail.cfm?releaseid=973347"},{"key":"e_1_2_7_21_1","unstructured":"Business Wire. Alkermes\u2019 new drug application for Aripiprazole Lauroxil for treatment of Schizophrenia accepted for filing by U.S. FDA. [Cited 22 February 2017.] Available from URL:http:\/\/www.businesswire.com\/news\/home\/20141022005161\/eNAlkermes%E2%80%99-Drug-Application-Aripiprazole-Lauroxil-Treatment-Schizophrenia"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09741"},{"key":"e_1_2_7_23_1","unstructured":"RxWiki. Reckitt Benckiser Pharmaceuticals Inc.Multiple ascending dose study of the safety tolerability pharmacokinetic\/efficacy. [Cited 22 February 2017.] Available from URL:http:\/\/www.rxwiki.com\/clinical\u2010trial\/multiple\u2010ascending\u2010dose\u2010study\u2010safety\u2010tolerability\u2010pharmacokineticefficacy"},{"key":"e_1_2_7_24_1","unstructured":"Clinical trials.gov. Safety tolerability and pharmacokinetics of iloperidone depot in schizophrenic patients. Last Update Posted: 22 January 2014.ClinicalTrials.govIdentifier: NCT01348100. [Cited 29 November 2017.] Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01348100"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000246217.34024.53"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02743.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000245563.06660.0f"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.63.5.683"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033474"},{"key":"e_1_2_7_31_1","first-page":"b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta\u2010analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"21","author":"Ioannidis JPA","year":"2009","journal-title":"Br. Med. J."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07530"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.134213"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.12.013"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m11201"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0785-y"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0231-7"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10467"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000140"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000038"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2017.05.004"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0512"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.07081221"},{"key":"e_1_2_7_44_1","unstructured":"EMEA608654\/2008. EMEA. Assessment report for Zyphadera. [Cited 22 February 2017.] Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Public_assessment_report\/human\/000890\/WC500054428.pdf"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110372817"},{"key":"e_1_2_7_46_1","first-page":"263","article-title":"Paliperidone palmitate once\u2010monthly injectable reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double\u2010blind, randomized study of schizoaffective disorder","volume":"6","author":"Fu DJ","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000535"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1017"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09584"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.12.012"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000444"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4310"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179049"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.08.015"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1507-8"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1358-3"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000494"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125317753332"},{"key":"e_1_2_7_59_1","first-page":"1483","article-title":"Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: An open\u2010label, single\u2010arm, prospective, interventional study","volume":"11","author":"Si T","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12201"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-26"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.09.638"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115586284"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2014.11.006"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.08.014"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000155"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/08039488.2017.1420819"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S151174"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw018"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-018-0089-9"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.2165\/11203810-000000000-00000"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.05.014"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0804"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00761.x"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.03.004"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.111"},{"key":"e_1_2_7_77_1","first-page":"23","article-title":"A prospective study comparing the long\u2010term effectiveness of injectable risperidone long\u2010acting therapy and oral aripiprazole in patients with schizophrenia","volume":"7","author":"MacFadden W","year":"2010","journal-title":"Psychiatry"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005987"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbu067"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125315623168"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125315623584"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200505000-00001"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105056514"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2003.11.007"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46014"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1239541"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/10401230701332931"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1067"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S20589"},{"key":"e_1_2_7_90_1","first-page":"6","article-title":"One\u2010year treatment continuation in patients prescribed risperidone long\u2010acting injection in New Zealand: A retrospective study","volume":"7","author":"Wheeler A","year":"2012","journal-title":"Clin. Schizophr. Rel. Psy."},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318167269d"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04427"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000030"},{"key":"e_1_2_7_94_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JCP.0000000000000827","article-title":"Comparison of paliperidone palmitate and risperidone long\u2010acting injection in schizophrenic patients. Results from a multicenter retrospective cohort study in France","volume":"38","author":"Limosin F","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.08.008"},{"key":"e_1_2_7_96_1","unstructured":"Risperidone Long Acting Injection (risperidone LAI)\/Risperdal Consta. Pennine care. NHS Foundation trust. Pennine care. [Cited 22 February 2017.] Available from URL:http:\/\/gmmmg.nhs.uk\/docs\/ip\/Archived%20Risperidone%20LAI%20%20SCG%20FINAL%20Approved%20DT%20Committee%2013%20August%202010.pdf"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-6-3"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000479"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.05.025"},{"key":"e_1_2_7_100_1","first-page":"19","article-title":"Relapse prevention and recovery in the treatment of schizophrenia","volume":"67","author":"Schooler NR","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.116.187989"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbu128"},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14com09541"},{"key":"e_1_2_7_104_1","unstructured":"Medscape.Drugs & Diseases. Aripiprazole (Rx). [Cited 4 January 2018.] Available from URL:https:\/\/reference.medscape.com\/drug\/abilify\u2010maintena\u2010aristada\u2010aripiprazole\u2010342983"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.16m02005"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs150"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.07.018"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314545614"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.11.020"},{"key":"e_1_2_7_110_1","first-page":"88","article-title":"Injectable paliperidone palmitate for schizophrenia","volume":"51","year":"2009","journal-title":"Med Lett."},{"key":"e_1_2_7_111_1","unstructured":"KondoK LowA JindaiK. Interventions to improve pharmacological adherence among adults with psychotic spectrum disorders bipolar disorder and posttraumatic stress disorder. VA ESP Project #05\u2013225;2015."},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312474019"},{"key":"e_1_2_7_113_1","unstructured":"HopewellS.Introduction to systematic reviews. Centre for Statistics in Medicine University of Oxford. [Cited 23 February 2017.] Available from URL:http:\/\/www.equator\u2010network.org\/wp\u2010content\/uploads\/2014\/09\/Systematic\u2010reviews\u2010Part\u20102.pdf"},{"key":"e_1_2_7_114_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.31887\/DCNS.2011.13.2\/ccorrell","article-title":"Randomized controlled trials in schizophrenia: Opportunities, limitations, and trial design alternatives","volume":"13","author":"Correll CU","year":"2011","journal-title":"Dialog. Clin. Neurosci."},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_7_116_1","unstructured":"LaMorfeWW. Boston University School of Public Health. Selection bias in cohort studies. [Cited 25 October 2018.] Available from URL:http:\/\/sphweb.bumc.bu.edu\/otlt\/MPH\u2010Modules\/EP\/EP713_Bias\/EP713_Bias3.html"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1542\/neo.15-12-e558"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.11.015"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-6-8"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpcn.12824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.12824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pcn.12824","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.12824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T03:01:46Z","timestamp":1694228506000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.12824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":118,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/pcn.12824"],"URL":"https:\/\/doi.org\/10.1111\/pcn.12824","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"2018-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}